- – New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued –
- – Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company's Phase 3 registrational study –
- – Zorevunersen generally well-tolerated across the studies –
- – Data presented for the first time at the 15th European Epilepsy Congress (EEC) –
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Seizure Reduction And Cognitive Improvements In Dravet Syndrome
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.